The Guardian declares mRNA vaccines as the future.
CEPI funds Phase 3 Trials of
Moderna's influenza vaccine candidate due to promising efficacy results. Meanwhile, the FDA considers severe black box warnings for COVID-19 vaccines.
Moderna receives $54.3M investment for bird flu vaccine following federal contract termination. Despite pauses in several vaccine areas, Moderna has secured a $1.5B loan to foster growth. Amid setbacks, Moderna unveils promising efficiency results in flu vaccine trials, boosting stock performance. The UK has launched its first moderna mRNA Vaccine Centre accompanied by a £50 Million Life-Sciences Fund. Even as the Moderna stock experiences fluctuation, the company continues to expand its mRNA manufacturing in the US. Notable collaboration with
Nanexa aims to enhance Moderna’s mRNA drug delivery. In a surprising revelation, Moderna withdraws its application for Flu/COVID-19 Combo Vaccine Candidate. But it continues to find resiliency as Moderna recently broke out above the 50-Day Moving Average. The downfall of some mRNA vaccine supports impacts Moderna.
HHS cancels late-stage development of a Moderna vaccine candidate, and Moderna stops work on its mRNA-1647 CMV Vaccine after demonstrating little protective effect in phase 3.
Moderna MRNA News Analytics from Sat, 24 May 2025 07:00:00 GMT to Thu, 01 Jan 2026 22:58:00 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -4
